Editorial: Statins and Liver Disease: Is it Time to Recommend Statins to Prevent Liver Disease Progression?
Editorial: Statins and Liver Disease: Is it Time to Recommend Statins to Prevent Liver Disease Progression?
复制标题
社论：他汀类药物和肝病：是时候推荐他汀类药物来预防肝病进展了吗？
DOI：
10.1038/ajg.2017.250
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Tien,PhyllisC
中科院分区：
文献类型：
--
作者：
Price,JenniferC;Tien,PhyllisC
有证据表明，他汀类药物可能会减少慢性肝病患者的肝脏相关不良后果。在本期《美国胃肠病学杂志》中，Kamalet等人在他们的荟萃分析中发现，他汀类药物的使用与纤维化进展、失代偿性肝硬化和死亡率的风险降低有关。这些令人鼓舞的发现表明他汀类药物对肝脏有益。然而，证据的总体质量较低，因为纳入荟萃分析的10项研究中有9项是观察性的。在常规推荐他汀类药物预防肝脏相关的发病率和死亡率之前，需要进行更可靠的研究，包括随机试验和晚期肝病患者的安全性研究。
Evidence is emerging that statins may reduce liver-related adverse outcomes in individuals with chronic liver disease. In this issue of theAmerican Journal of Gastroenterology, Kamalet al. found in their meta-analysis that statin use was associated with a reduced risk of fibrosis progression, decompensated cirrhosis, and mortality. These encouraging findings suggest beneficial liver effects of statins. However, the overall quality of the evidence is low because 9 of the 10 studies included in the meta-analysis were observational. More robust studies, including randomized trials and research on safety in patients with advanced liver disease, are needed before statins can be routinely recommended for prevention of liver-related morbidity and mortality.